<?xml version="1.0" encoding="UTF-8"?>
<p>Repurposing of known drugs could significantly accelerate the deployment of novel therapies for COVID-19. The main difference of data-driven approach from the structure-activity-relationship approach is in use of databases of drugs, including phytochemical ones (
 <ext-link ext-link-type="uri" xlink:href="https://www.drugbank.ca" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.drugbank.ca</ext-link>, 
 <ext-link ext-link-type="uri" xlink:href="http://drugcentral.org" xmlns:xlink="http://www.w3.org/1999/xlink">http://drugcentral.org</ext-link> etc.). The identification of new areas of application for already known drugs saves time for testing their biosafety, but does not provide an opportunity to find fundamentally new substances that can be more effective than previously known drugs. The approach includes three steps:
</p>
